Canada's Voice For
Biotechnology
Members
| Location: |
Saint-Hubert, Quebec |
| Industry Sector: |
Biotechnology / R&D Services |
| Website: |
www.kabs.com |
| Contact: |
Jean-Simon Blais (jsblais@kabs.com)
1 450 6564404
|
| Description: |
K.A.B.S. Pharmaceutical Services offers a broad range of analytical services, formulation development and pilot manufacturing to the bio-pharmaceutical industry. |
| Location: |
Vancouver, British Columbia |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.kalgene.com |
| Contact: |
T. Nathan Yoganathan (nathan@kalgene.com)
1 604 3754519
|
| Description: |
KalGene Pharmaceuticals Inc. is a privately-held Canadian company focused on the development of oncology therapeutics and companion diagnostics. |
| Location: |
Winnipeg, Manitoba |
| Industry Sector: |
Medical Technology |
| Website: |
www.kanebiotech.com |
| Contact: |
Gord Froehlich (info@kanebiotech.com)
1 204 4531301
|
| Ownership: |
Public - Toronto Stock Exchange (TSX): KNE.V |
| Description: |
Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms. |
| Location: |
Edmonton, Alberta |
| Industry Sector: |
Biotechnology / R&D Services |
| Website: |
www.kmthepatech.com |
| Contact: |
Svetlana Sapelnikova (ssapelnikova@kmthepatech.com)
|
| Description: |
KMT Hepatech, Inc. provides unique in vivo research services utilizing proprietary platform technology of small animal model, the KMT Mouse. The KMT Mouse is a chimeric mouse model with humanized liver with up to 95% of stable human hepatocyte engraftment. Human hepatocytes repopulate the mouse liver in an organized fashion and retain long term normal pharmacological responses. Human hepatocytes in the mouse liver are functional and secrete a variety of hepatic proteins like albumin, α-1 antitrypsin, apolipoprotein A, apolipoprotein E and several clotting factors and complement proteins. Upon engraftment, the KMT Mouse can be successfully infected with hepatotropic infections (hepatitis C, hepatitis B or malaria) and remain infected over an extended period of time. This is widely used for hepatitis C (HCV) and hepatitis B (HBV) drug development. The non-infected KMT Mouse can be utilized to address early evaluation of human toxicity in hepatocytes and characterization of human metabolism. This application is beneficial for early safety assessments. The company is proud to acknowledge that generated in KMT Mouse drug therapy responses are predictive of those seen in humans during clinical trials. KMT Mouse platform technology is a cost effective animal model that contributes important advantages to research on Hepatitis C and other hepatotropic infections, as well as toxicity and drug metabolsm studies. KMT Hepatech, Inc. owns an international patent portfolio that includes coverage of the uPA chimeric mouse model of HCV infection and on the uPA chimeric mouse for all potential applications including HBV, malaria and studies of toxicity, drug and lipoprotein metabolism. The technology is available for out-licensing. KMT Hepatech is considering in-licensing (murine models). |
| Location: |
Gyeonggi-do, |
| Industry Sector: |
Public / Non-Profit Organizations |
| Website: |
www.koreabio.org |
| Contact: |
Jeong-Sun Seo (info@koreabio.org)
82 2 552 4771
|
| Description: |
KoreaBio is a non-profit organization and a trade association. Their mission is to become a supportive organization to serve the member companies more efficiently and a reliable partner of the government. |
| Location: |
Toronto, Ontario |
| Industry Sector: |
Professional Services and Consulting |
| Website: |
www.kpmg.ca |
| Contact: |
Mary Lou Maher
1 416 7778500
|
| Ownership: |
Subsidiary - : |
| Description: |
KPMG in Canada’s industry experience and deep technical knowledge help to differentiate us in the marketplace. Through a global network, our biotechnology clients have access to nearly 140,000 professionals in 145 countries, including more than 30 offices in Canada. |
